Watchlist Price Alert

Ashland Inc. (ASH)

NYSE: ASH · Real-Time Price · USD

49.93

1.56 (3.23%)

At close: May 08, 2025, 3:59 PM

49.90

-0.06%

After-hours: May 08, 2025, 07:52 PM EDT

3.23% (1D)

Bid	49.89
Market Cap	2.28B
Revenue (ttm)	1.95B
Net Income (ttm)	-125M
EPS (ttm)	-1.88
PE Ratio (ttm)	-26.56
Forward PE	9.13
Analyst	Buy

Ask	49.97
Volume	422,759
Avg. Volume (20D)	769,573
Open	48.52
Previous Close	48.37
Day's Range	48.52 - 50.12
52-Week Range	45.21 - 102.50
Beta	0.57

About ASH

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ASH

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ASH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Ashland has released their quartely earnings on Apr 30, 2025:

Revenue of $479M misses estimates by $23.62M, with -16.70% YoY decline.

EPS of 0.99 misses estimates by -0.11, with -22.05% YoY decline.

Why Price Moved

1 week ago

-9.85%

Ashland shares are trading lower after the company... Unlock content with Pro Subscription

1 month ago

+4.9%

Ashland shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $68 to $71.

News

2 days ago · zacks.com

Ashland's Q2 Earnings and Revenues Miss Estimates, Down Y/Y

ASH's fiscal second-quarter sales are adversely impacted by the portfolio optimization actions.

1 week ago · seekingalpha.com

Ashland, Inc. (ASH) Q2 2025 Earnings Call Transcript

Ashland, Inc. (NYSE:ASH ) Q2 2025 Earnings Conference Call May 1, 2025 10:00 AM ET Company Participants William Whitaker - VP, Finance & Director, IR Guillermo Novo - Chairman & CEO John Willis - SVP,...

1 week ago · zacks.com

Ashland (ASH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Ashland (ASH) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates...

1 week ago · zacks.com

Ashland (ASH) Lags Q2 Earnings and Revenue Estimates

Ashland (ASH) came out with quarterly earnings of $0.99 per share, missing the Zacks Consensus Estimate of $1.10 per share. This compares to earnings of $1.27 per share a year ago.

2 weeks ago · zacks.com

Earnings Preview: Ashland (ASH) Q2 Earnings Expected to Decline

Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · zacks.com

Ashland Wraps Up Expansion of Pharmaceutical Plant in Brazil

ASH is investing in modernizing equipment for microbial protection in personal care applications at its Technical Center in Sao Paulo.

1 month ago · zacks.com

Ashland Wraps Up Divestment of Avoca Business to Mane

ASH closes the sales of its Avoca business, the last entity remaining from the Pharmachem acquisition.

2 months ago · seekingalpha.com

Ashland Presents Attractive Upside Emerging From The Downcycle

Ashland is generating attractive free cash flow and is well-positioned to achieve its 2027 target of $600 million EBITDA and 50% FCF conversion rate. Despite the stock selling off over the last 8 mont...

2 months ago · seekingalpha.com

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are...